Literature DB >> 11399544

The hair follicle as a target for gene therapy.

S Gupta1, A Domashenko, G Cotsarelis.   

Abstract

The hair follicle possesses progenitor cells for continued hair follicle cycling and for epidermal keratinocytes, melanocytes and Langerhans cells. These different cell types can be targeted by topical gene delivery to mouse skin. Using a combination of liposomes and DNA, we demonstrated the feasibility of targeting hair follicle cells in human scalp xenografts as well. We defined liposome composition and stage of the hair cycle as important parameters influencing transfection of human hair follicles. Transfection occurred only during anagen onset. Considerations and obstacles for using gene therapy to treat alopecias and skin disease are discussed. A theoretical framework for future gene therapy treatments for cutaneous and systemic disorders is presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399544

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  4 in total

Review 1.  What you always needed to know about electroporation based DNA vaccines.

Authors:  Anita Gothelf; Julie Gehl
Journal:  Hum Vaccin Immunother       Date:  2012-10-30       Impact factor: 3.452

2.  Immune-mediated loss of transgene expression in skin: implications for cutaneous gene therapy.

Authors:  Soosan Ghazizadeh; Richard S Kalish; Lorne B Taichman
Journal:  Mol Ther       Date:  2003-03       Impact factor: 11.454

3.  Hair follicles contribute significantly to penetration through human skin only at times soon after application as a solvent deposited solid in man.

Authors:  Xin Liu; Jeff E Grice; Juergen Lademann; Nina Otberg; Sindy Trauer; Alexa Patzelt; Michael S Roberts
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

4.  An integrated pharmacokinetic and imaging evaluation of vehicle effects on solute human epidermal flux and, retention characteristics.

Authors:  G Winckle; Y G Anissimov; S E Cross; G Wise; M S Roberts
Journal:  Pharm Res       Date:  2007-09-22       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.